Atara Biotherapeutics (NASDAQ:ATRA) Trading Up 6.3%

Atara Biotherapeutics Inc (NASDAQ:ATRA)’s stock price was up 6.3% on Thursday . The stock traded as high as $20.31 and last traded at $20.25. Approximately 656,364 shares changed hands during mid-day trading, an increase of 11% from the average daily volume of 589,642 shares. The stock had previously closed at $19.05.

Several analysts have recently weighed in on ATRA shares. ValuEngine lowered shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 17th. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, April 30th. Mizuho restated a “buy” rating and set a $62.00 price target on shares of Atara Biotherapeutics in a research note on Thursday, May 9th. William Blair restated a “buy” rating on shares of Atara Biotherapeutics in a research note on Thursday, May 16th. Finally, Roth Capital started coverage on shares of Atara Biotherapeutics in a research note on Thursday, May 30th. They set a “buy” rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the stock. Atara Biotherapeutics has an average rating of “Buy” and a consensus target price of $40.40.

The stock’s 50 day simple moving average is $22.70. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.96 and a current ratio of 9.96.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.44) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.48) by $0.04. Equities analysts forecast that Atara Biotherapeutics Inc will post -5.54 earnings per share for the current year.

In other Atara Biotherapeutics news, insider Joe Newell sold 1,500 shares of Atara Biotherapeutics stock in a transaction on Monday, April 1st. The shares were sold at an average price of $39.96, for a total transaction of $59,940.00. Following the transaction, the insider now directly owns 63,646 shares of the company’s stock, valued at approximately $2,543,294.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Isaac E. Ciechanover sold 3,900 shares of Atara Biotherapeutics stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $37.04, for a total transaction of $144,456.00. Following the transaction, the chief executive officer now directly owns 332,243 shares in the company, valued at $12,306,280.72. The disclosure for this sale can be found here. Insiders have sold a total of 28,350 shares of company stock valued at $845,543 in the last 90 days. 7.00% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Rhumbline Advisers raised its holdings in Atara Biotherapeutics by 51.2% during the 4th quarter. Rhumbline Advisers now owns 56,305 shares of the biotechnology company’s stock worth $1,956,000 after purchasing an additional 19,062 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Atara Biotherapeutics by 278.5% in the 4th quarter. SG Americas Securities LLC now owns 9,929 shares of the biotechnology company’s stock valued at $345,000 after acquiring an additional 7,306 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in shares of Atara Biotherapeutics by 31.7% in the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 4,042 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 974 shares in the last quarter. California Public Employees Retirement System increased its stake in shares of Atara Biotherapeutics by 8.4% in the 4th quarter. California Public Employees Retirement System now owns 50,240 shares of the biotechnology company’s stock valued at $1,745,000 after acquiring an additional 3,874 shares in the last quarter. Finally, Tocqueville Asset Management L.P. increased its stake in shares of Atara Biotherapeutics by 9.2% in the 4th quarter. Tocqueville Asset Management L.P. now owns 11,825 shares of the biotechnology company’s stock valued at $411,000 after acquiring an additional 1,000 shares in the last quarter.

About Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.